While cannabinoids offer a potential alternative for refractory chronic pain, optimal use requires personalized dosing and ...

Chronic pain affects approximately 1 in 5 Americans, and yet it remains one of the most misunderstood and challenging medical ...

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

In today’s fast-paced world, maintaining optimal nerve health is paramount for overall well-being. Nerve-related issues can ...

It’s usually chronic (long-term) and may get progressively worse. Certain conditions, such as diabetes, may increase your risk of neuropathy, which could lead to neuropathic pain. CBD lotions ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...

Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

It is important to add pain management to leprosy treatment protocols. This can reduce the challenges that patients face. Read on.